| Target General Infomation |
| Target ID |
T89055
|
| Former ID |
TTDNC00613
|
| Target Name |
MEK-2 protein kinase
|
| Gene Name |
MAP2K2
|
| Synonyms |
Dual specificity mitogenactivated protein kinase kinase 2; ERK activator kinase 2; MAP kinase kinase 2; MAPK/ERK kinase 2; MAPKK 2; MEK 2; MAP2K2
|
| Target Type |
Discontinued
|
| Disease |
Cancer [ICD9: 140-229; ICD10: C00-C96] |
|---|
| Function |
Catalyzes the concomitant phosphorylation of a threonineand a tyrosine residue in a Thr-Glu-Tyr sequence located in MAP kinases. Activates the ERK1 and ERK2 MAP kinases (By similarity).
|
| BioChemical Class |
Kinase
|
| UniProt ID |
|
| EC Number |
EC 2.7.12.2
|
| Sequence |
MLARRKPVLPALTINPTIAEGPSPTSEGASEANLVDLQKKLEELELDEQQKKRLEAFLTQ
KAKVGELKDDDFERISELGAGNGGVVTKVQHRPSGLIMARKLIHLEIKPAIRNQIIRELQ
VLHECNSPYIVGFYGAFYSDGEISICMEHMDGGSLDQVLKEAKRIPEEILGKVSIAVLRG
LAYLREKHQIMHRDVKPSNILVNSRGEIKLCDFGVSGQLIDSMANSFVGTRSYMAPERLQ
GTHYSVQSDIWSMGLSLVELAVGRYPIPPPDAKELEAIFGRPVVDGEEGEPHSISPRPRP
PGRPVSGHGMDSRPAMAIFELLDYIVNEPPPKLPNGVFTPDFQEFVNKCLIKNPAERADL
KMLTNHTFIKRSEVEEVDFAGWLCKTLRLNQPGTPTRTAV
|
| Structure |
1S9I; 4H3Q
|
| Drugs and Mode of Action |
| Drug(s) |
RDEA-436 |
Drug Info |
Discontinued in Phase 1 |
Cancer |
[1] |
|---|
| Inhibitor |
RDEA-436 |
Drug Info |
[2] |
|---|
| Target Expression Profile (TEP) and Drug Resistance Mutation (DRM) |
| TEP |
EXP Info
|
| DRM |
DRM Info
|
| Pathways |
|
KEGG Pathway
|
MAPK signaling pathway
|
|
ErbB signaling pathway
|
|
Ras signaling pathway
|
|
Rap1 signaling pathway
|
|
cGMP-PKG signaling pathway
|
|
cAMP signaling pathway
|
|
HIF-1 signaling pathway
|
|
FoxO signaling pathway
|
|
Sphingolipid signaling pathway
|
|
PI3K-Akt signaling pathway
|
|
Vascular smooth muscle contraction
|
|
VEGF signaling pathway
|
|
Gap junction
|
|
Signaling pathways regulating pluripotency of stem cells
|
|
Toll-like receptor signaling pathway
|
|
Natural killer cell mediated cytotoxicity
|
|
T cell receptor signaling pathway
|
|
B cell receptor signaling pathway
|
|
Fc epsilon RI signaling pathway
|
|
Long-term potentiation
|
|
Neurotrophin signaling pathway
|
|
Long-term depression
|
|
Regulation of actin cytoskeleton
|
|
Insulin signaling pathway
|
|
GnRH signaling pathway
|
|
Estrogen signaling pathway
|
|
Melanogenesis
|
|
Prolactin signaling pathway
|
|
Thyroid hormone signaling pathway
|
|
Oxytocin signaling pathway
|
|
Prion diseases
|
|
Hepatitis B
|
|
Influenza A
|
|
Pathways in cancer
|
|
Proteoglycans in cancer
|
|
MicroRNAs in cancer
|
|
Renal cell carcinoma
|
|
Endometrial cancer
|
|
Glioma
|
|
Prostate cancer
|
|
Thyroid cancer
|
|
Melanoma
|
|
Bladder cancer
|
|
Chronic myeloid leukemia
|
|
Acute myeloid leukemia
|
|
Non-small cell lung cancer
|
|
Central carbon metabolism in cancer
|
|
Choline metabolism in cancer
|
|
NetPath Pathway
|
TGF_beta_Receptor Signaling Pathway
|
|
PANTHER Pathway
|
Angiogenesis
|
|
B cell activation
|
|
EGF receptor signaling pathway
|
|
Endothelin signaling pathway
|
|
FGF signaling pathway
|
|
Insulin/IGF pathway-mitogen activated protein kinase kinase/MAP kinase cascade
|
|
Integrin signalling pathway
|
|
PDGF signaling pathway
|
|
T cell activation
|
|
Toll receptor signaling pathway
|
|
VEGF signaling pathway
|
|
Ras Pathway
|
|
Angiotensin II-stimulated signaling through G proteins and beta-arrestin
|
|
CCKR signaling map ST
|
|
Pathway Interaction Database
|
Fc-epsilon receptor I signaling in mast cells
|
|
Endothelins
|
|
GMCSF-mediated signaling events
|
|
Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met)
|
|
SHP2 signaling
|
|
Netrin-mediated signaling events
|
|
mTOR signaling pathway
|
|
IL2-mediated signaling events
|
|
Ceramide signaling pathway
|
|
ErbB1 downstream signaling
|
|
ErbB2/ErbB3 signaling events
|
|
PDGFR-beta signaling pathway
|
|
Nongenotropic Androgen signaling
|
|
CXCR3-mediated signaling events
|
|
Signaling events mediated by Stem cell factor receptor (c-Kit)
|
|
Signaling events mediated by VEGFR1 and VEGFR2
|
|
Cellular roles of Anthrax toxin
|
|
Downstream signaling in na&
|
|
#xef
|
|
ve CD8+ T cells
|
|
PathWhiz Pathway
|
Intracellular Signalling Through Adenosine Receptor A2a and Adenosine
|
|
Intracellular Signalling Through Adenosine Receptor A2b and Adenosine
|
|
Fc Epsilon Receptor I Signaling in Mast Cells
|
|
Insulin Signalling
|
|
Reactome
|
MAPK1 (ERK2) activation
|
|
Uptake and function of anthrax toxins
|
|
RAF activation
|
|
MAP2K and MAPK activation
|
|
Negative feedback regulation of MAPK pathway
|
|
WikiPathways
|
Toll-like receptor signaling pathway
|
|
Serotonin Receptor 4/6/7 and NR3C Signaling
|
|
Serotonin Receptor 2 and ELK-SRF/GATA4 signaling
|
|
Serotonin HTR1 Group and FOS Pathway
|
|
TCR Signaling Pathway
|
|
Hypothetical Network for Drug Addiction
|
|
EPO Receptor Signaling
|
|
Regulation of Actin Cytoskeleton
|
|
IL-2 Signaling Pathway
|
|
Insulin Signaling
|
|
EGF/EGFR Signaling Pathway
|
|
MAPK Cascade
|
|
MAPK Signaling Pathway
|
|
TGF beta Signaling Pathway
|
|
IL-6 signaling pathway
|
|
Signaling of Hepatocyte Growth Factor Receptor
|
|
Kit receptor signaling pathway
|
|
Bladder Cancer
|
|
Cardiac Hypertrophic Response
|
|
MAP kinase activation in TLR cascade
|
|
RAF/MAP kinase cascade
|
|
Nanoparticle-mediated activation of receptor signaling
|
|
Structural Pathway of Interleukin 1 (IL-1)
|
|
Genes and (Common) Pathways Underlying Drug Addiction
|
|
Amyotrophic lateral sclerosis (ALS)
|
|
BDNF signaling pathway
|
|
Oncostatin M Signaling Pathway
|
|
Interleukin-11 Signaling Pathway
|
|
B Cell Receptor Signaling Pathway
|
|
Prostate Cancer
|
|
Signaling Pathways in Glioblastoma
|
|
TSLP Signaling Pathway
|
|
IL-9 Signaling Pathway
|
|
IL-7 Signaling Pathway
|
|
Leptin signaling pathway
|
|
IL-1 signaling pathway
|
|
Signaling by FGFR
|
|
Integrin-mediated Cell Adhesion
|
|
L1CAM interactions
|
|
MicroRNAs in cardiomyocyte hypertrophy
|
|
Regulation of toll-like receptor signaling pathway
|
|
IL-5 Signaling Pathway
|
| References |
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800028258) |
|---|
| REF 2 | Clinical pipeline report, company report or official report of MedKoo Biosciences. |
|---|
